SymBio shifts bendamustine's multiple myeloma focus to second-line use
This article was originally published in Scrip
Executive Summary
SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.